Surrozen (NASDAQ:SRZN) Director Buys $110,404.77 in Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey acquired 5,523 shares of the business’s stock in a transaction that occurred on Wednesday, January 14th. The shares were acquired at an average cost of $19.99 per share, with a total value of $110,404.77. Following the transaction, the director directly owned 999,429 shares in the company, valued at $19,978,585.71. The trade was a 0.56% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 13th, Tim Kutzkey purchased 12,470 shares of Surrozen stock. The stock was acquired at an average cost of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey purchased 15,100 shares of Surrozen stock. The shares were acquired at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The stock was bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The shares were bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The shares were bought at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Price Performance

NASDAQ SRZN opened at $20.00 on Friday. The firm has a market capitalization of $171.40 million, a price-to-earnings ratio of -0.90 and a beta of 0.58. The company’s fifty day moving average is $18.70 and its two-hundred day moving average is $13.95. Surrozen, Inc. has a 52-week low of $5.90 and a 52-week high of $24.94.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The company had revenue of $0.98 million for the quarter. As a group, sell-side analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Stempoint Capital LP lifted its holdings in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after acquiring an additional 445,713 shares during the period. Braidwell LP bought a new stake in shares of Surrozen in the 2nd quarter worth about $1,252,000. Millennium Management LLC acquired a new stake in shares of Surrozen during the 3rd quarter worth about $1,414,000. Schonfeld Strategic Advisors LLC bought a new position in Surrozen during the 3rd quarter valued at about $889,000. Finally, Armistice Capital LLC bought a new position in Surrozen during the 2nd quarter valued at about $536,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.